AU2016303622B2 - Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor - Google Patents

Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor Download PDF

Info

Publication number
AU2016303622B2
AU2016303622B2 AU2016303622A AU2016303622A AU2016303622B2 AU 2016303622 B2 AU2016303622 B2 AU 2016303622B2 AU 2016303622 A AU2016303622 A AU 2016303622A AU 2016303622 A AU2016303622 A AU 2016303622A AU 2016303622 B2 AU2016303622 B2 AU 2016303622B2
Authority
AU
Australia
Prior art keywords
mdsc
mdscs
asc
gvhd
deficient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016303622A
Other languages
English (en)
Other versions
AU2016303622A8 (en
AU2016303622A1 (en
Inventor
Bruce R. Blazar
Brent H. KOEHN
Jeff S. MILLER
Peter J. Murray
Jenny P. Y. TING
Robert ZEISER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Ludwigs Universitaet Freiburg
Murray Peter J Dr
University of North Carolina at Chapel Hill
St Jude Childrens Research Hospital
University of Minnesota System
Original Assignee
Albert Ludwigs Universitaet Freiburg
Murray Peter J Dr
University of North Carolina at Chapel Hill
St Jude Childrens Research Hospital
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Ludwigs Universitaet Freiburg, Murray Peter J Dr, University of North Carolina at Chapel Hill, St Jude Childrens Research Hospital, University of Minnesota System filed Critical Albert Ludwigs Universitaet Freiburg
Publication of AU2016303622A1 publication Critical patent/AU2016303622A1/en
Publication of AU2016303622A8 publication Critical patent/AU2016303622A8/en
Application granted granted Critical
Publication of AU2016303622B2 publication Critical patent/AU2016303622B2/en
Priority to AU2022228188A priority Critical patent/AU2022228188A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0648—Splenocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
AU2016303622A 2015-08-06 2016-08-05 Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor Ceased AU2016303622B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022228188A AU2022228188A1 (en) 2015-08-06 2022-09-09 Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201990P 2015-08-06 2015-08-06
US62/201,990 2015-08-06
PCT/US2016/045739 WO2017024213A1 (en) 2015-08-06 2016-08-05 Modulating inflammasome activation of myeloid-derived supperssor cells for treating gvhd or tumor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022228188A Division AU2022228188A1 (en) 2015-08-06 2022-09-09 Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor

Publications (3)

Publication Number Publication Date
AU2016303622A1 AU2016303622A1 (en) 2018-02-22
AU2016303622A8 AU2016303622A8 (en) 2018-05-31
AU2016303622B2 true AU2016303622B2 (en) 2022-07-07

Family

ID=56686964

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016303622A Ceased AU2016303622B2 (en) 2015-08-06 2016-08-05 Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
AU2022228188A Abandoned AU2022228188A1 (en) 2015-08-06 2022-09-09 Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022228188A Abandoned AU2022228188A1 (en) 2015-08-06 2022-09-09 Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor

Country Status (9)

Country Link
US (2) US10894061B2 (enExample)
EP (3) EP3682889B1 (enExample)
JP (3) JP6927499B2 (enExample)
CN (2) CN108883131B (enExample)
AU (2) AU2016303622B2 (enExample)
CA (1) CA2993806A1 (enExample)
ES (2) ES2789574T3 (enExample)
PT (1) PT3682889T (enExample)
WO (1) WO2017024213A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3682889B1 (en) * 2015-08-06 2023-02-01 Regents of the University of Minnesota Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
FR3100715B1 (fr) * 2019-09-12 2023-09-29 Francais Du Sang Ets Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte
WO2022216615A1 (en) * 2021-04-05 2022-10-13 Rhode Island Hospital Compositions and methods for the prevention or treatment of rheumatoid arthritis
CN113707223A (zh) * 2021-04-21 2021-11-26 吴安华 一种预测肿瘤炎性小体活性状态及治疗敏感性的基因集系统及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062990A1 (en) * 2008-11-26 2010-06-03 Mount Sinai School Of Medicine Of New York University In vitro generation of myeloid derived suppressor cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136973A1 (en) 2002-11-07 2004-07-15 Eliezer Huberman Human stem cell materials and methods
EP2300000A1 (en) 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
US8951529B2 (en) 2009-12-22 2015-02-10 Icahn School Of Medicine At Mount Sinai Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases
US20140377278A1 (en) 2012-01-10 2014-12-25 Yale University Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders
AR095882A1 (es) * 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
JP6359013B2 (ja) 2013-07-29 2018-07-18 国立大学法人 鹿児島大学 １，５−ｄ−アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬
LT3240801T (lt) * 2014-12-31 2021-02-25 Checkmate Pharmaceuticals, Inc. Kombinuota navikų imunoterapija
JP6959865B2 (ja) * 2015-01-21 2021-11-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ガイドとして自身のカルレティキュリンを使用して癌細胞を食べるマクロファージ
EP3682889B1 (en) * 2015-08-06 2023-02-01 Regents of the University of Minnesota Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
KR102599839B1 (ko) 2015-11-13 2023-11-09 큐에프 테크놀로지스 에이에스 물을 모으기 위한 장치 및 방법
GB201721185D0 (en) * 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
CN112646777B (zh) * 2020-12-31 2022-11-04 广州医科大学 一种扩增髓系来源的抑制性细胞的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062990A1 (en) * 2008-11-26 2010-06-03 Mount Sinai School Of Medicine Of New York University In vitro generation of myeloid derived suppressor cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HIGHFILL STEVEN L ET AL, BLOOD, (2010-08-31), vol. 116, no. 25, pages 5738 - 5747 *
JANKOVIC DRAGANA ET AL, "The Nlrp3 inflammasome regulates acute graft-versus-host disease", JOURNAL OF EXPERIMENTAL MEDICINE, (2013-09), vol. 210, no. 10, pages 1899 - 1910 *
MESSMANN JOANNA J ET AL, "In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity", BLOOD, (2015-07-16), vol. 126, no. 9, pages 1138 - 1148 *
ZHANG H. et al., "Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation", Clinical Immunology, April 2015, Vol. 157, No. 2, pages 175-186 *

Also Published As

Publication number Publication date
EP3331538B1 (en) 2020-03-11
EP4218776A3 (en) 2024-02-28
EP4218776A2 (en) 2023-08-02
WO2017024213A1 (en) 2017-02-09
PT3682889T (pt) 2023-03-09
US12234480B2 (en) 2025-02-25
CN108883131A (zh) 2018-11-23
ES2939534T3 (es) 2023-04-24
ES2789574T3 (es) 2020-10-26
CN114790447A (zh) 2022-07-26
AU2016303622A8 (en) 2018-05-31
CA2993806A1 (en) 2017-02-09
JP2018536620A (ja) 2018-12-13
HK1256917A1 (en) 2019-10-04
US20180214483A1 (en) 2018-08-02
EP3682889B1 (en) 2023-02-01
JP7235259B2 (ja) 2023-03-08
US20210128612A1 (en) 2021-05-06
JP2023053338A (ja) 2023-04-12
CN108883131B (zh) 2022-04-29
EP3682889A1 (en) 2020-07-22
EP3331538A1 (en) 2018-06-13
JP6927499B2 (ja) 2021-09-01
AU2016303622A1 (en) 2018-02-22
AU2022228188A1 (en) 2022-09-29
JP2021167345A (ja) 2021-10-21
US10894061B2 (en) 2021-01-19

Similar Documents

Publication Publication Date Title
Cai et al. All trans-retinoic acid protects against acute ischemic stroke by modulating neutrophil functions through STAT1 signaling
US12234480B2 (en) Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells
Jassar et al. Activation of tumor-associated macrophages by the vascular disrupting agent 5, 6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell–mediated antitumor immune response in murine models of lung cancer and mesothelioma
JP7432624B2 (ja) Ｎａｄ＋及び／又はｎａｄ＋阻害剤及び／又はｎａｄ＋アゴニストの使用及びその配合剤
Mohamed et al. Modulatory effects of levamisole and garlic oil on the immune response of Wistar rats: Biochemical, immunohistochemical, molecular and immunological study
US20230158112A1 (en) Targeting gamma-delta T Cells in Obesity and Cachexia
Kim et al. Impaired barrier integrity of the skeletal muscle vascular endothelium drives progression of cancer cachexia
HK40100442A (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
CN116139275B (zh) Cd300ld抑制剂在制备预防、诊断或治疗肿瘤产品中的用途
HK40023269A (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
HK40023269B (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
HK40077184A (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
HK1256917B (en) Modulating inflammasome activation of myeloid-derived supperssor cells for treating gvhd or tumor
HK1263409B (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
HK1263409A1 (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
Aliya The role of M2 macrophages in mediating resistance to radiotherapy in head and neck squamous cell carcinoma
Kalliara Single-cell investigation of macrophage activation and plasticity: focus on STAT1 and STAT6 signalling
Angarita‐Planchez et al. Monovalent mannose‐glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions
Nothbaum Exploration of the effect of interferon beta, natural killer cells and immune checkpoints on nasopharyngeal carcinoma in mouse model and cell culture
WO2017205779A2 (en) Compositions and methods for treating disorders related to inflammasome activity and il-1alpha expression
KR20220091426A (ko) 혈액 유래 물질 및 면역세포를 포함하는 암 또는 면역질환의 예방 또는 치료용 약학조성물
Yang et al. TLR7-agonist and antineoplastic MEK1/2-inhibitor combination unlocks interferon responses from macrophages
Savage Challenging Current Paradigms: Increasing the Efficacy of Radiation Therapy with Novel Radiation Schemes
Park YongMean et al. Eosinophil survival and apoptosis in health and disease.
Gaurnier-Hausser Angiocidin: A novel immunomodulatory molecule

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 32 , NO 7 , PAGE(S) 991 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME REGENTS OF THE UNIVERSITY OF MINNESOTA; THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL; ALBERT-LUDWIG UNIVERSITYY FREIBURG; ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., APPLICATION NO. 2016303622, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO ALBERT-LUDWIGS-UNIVERSITAET FREIBURG

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ MODULATING INFLAMMASOME ACTIVATION OF MYELOID-DERIVED SUPPRESSOR CELLS FOR TREATING GVHD OR TUMOR

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired